To mark Breast Cancer Awareness Month, we are pleased to share an animated video on treating metastatic breast cancer from Prof. Francois-Clement Bidard.
Explore how to optimise treatment selection and make appropriate sequencing decisions for patients with ER+/HER2- metastatic breast cancer, as Prof. Bidard explains:
- Why we should determine molecular characteristics for each patient
- When to perform ESR1 mutation testing
- Current treatment guidelines for ER+ metastatic breast cancer
Watch the video and download the accompanying slides below.
Marking Breast Cancer Awareness Month
To optimise treatment selection, molecular characterization should be conducted for each patient
ESR1 mutation testing should preferably be performed using a liquid biopsy platform when recurrence or progression occurs during endocrine therapy
Elacestrant was the 1st oral SERD to be FDA approved (January 2023), with optimal efficacy and manageable safety for patients with ESR1 mutated ER+/HER2- advanced or metastatic breast cancer
Oral SERDs are being studied as a monotherapy and in combination with targeted therapies, offering promising prospects for their integration into clinical practice